GT Biopharma doses first patient in GTB-5550 solid tumor trial

May 14, 2026 8:30 AM

GT Biopharma Inc. (NASDAQ: GTBP) has dosed the first patient in a Phase 1 trial evaluating GTB-5550, a B7-H3-targeted natural ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found